ZoBio developed a fast, biophysics-driven SPR approach to identify molecular glue fragments that stabilize interactions between a target and its desired protein partner.

ZoBio is a leading innovator that provides "gene to structure"​ research services in early stage drug discovery. The company is a privately held, self-funded and founded in 2004. We are specialized in 4 areas: 1) enabling proteins for biophysical and structural biology studies, 2) using biophysics to screen fragment libraries for selective ligands for a pharmaceutical target, 3) using both X-ray crystallography and NMR to provide 3D structural information on complexes of ligands bound to a protein and 4) using medicinal chemistry expertise to advance fragment "hits"​. 1) Every protein ZoBio produces is "crystallography"​ quality. For structurally unprecedented, challenging proteins, we offer our proprietary Protein Domain Trapping for screening millions of variants for high level expression of soluble, functional, monodisperse protein. 2) Orthogonal screening via our proprietary TINS NMR screening technology, SPR and high concentration, functional assays. Screen the highly optimized, poised ZoBio fragment library or your own. 3) Structural information from protein NMR and crystallography. The best of both worlds with more shots on goal to solve even the most difficult challenges. 4) Medicinal chemistry focused on bridging the challenging gap between fragment and hit. We bring deep understanding of chemistry and structural biology together to fully enable fragment based drug discovery.